Barrett's dysplasia and the Vienna classification: Reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry

Histopathology

Volumn 54, Issue 6, 2009, Pages 699-712

  Kaye, Philip V ^a,b   Haider, Syeda A ^b   Ilyas, Mohammed ^b   James, Peter D ^b   Soomro, Irshad ^b   Faisal, Wasek ^b   Catton, James ^b   Parsons, Simon L ^b   Ragunath, Krish ^b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Barrett; Carcinoma; Dysplasia; Oesophagus; P53

Indexed keywords

PROTEIN P53;

ARTICLE; BARRETT ESOPHAGUS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DYSPLASIA; ESOPHAGUS BIOPSY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERRATER RELIABILITY; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY;

BARRETT ESOPHAGUS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; PRECANCEROUS CONDITIONS; RANDOM ALLOCATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 65349095555     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03288.x     Document Type: Article

References (20)

1. Haggitt RC. Barrett's esophagus, dysplasia and adenocarcinoma. Hum. Pathol. 1994 25 982 993. (Pubitemid 24313642)
2. Skacel M, Petras RE, Gramlich TJ et al. The diagnosis of low grade dysplasia in Barrett's oesophagus and its implications for disease progression. Am. J. Gastroenterol. 2000 95 3383 3387.
3. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 2006 4 566 572. (Pubitemid 44308164)
4. Brithish Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. BSG guidelines. London : British Society of Gastroenterology, 2005.
5. Schlemper RJ, Kato Y, Stolte M. Review of histological classifications of gastrointestinal epithelial neoplasia: differences in diagnosis of early carcinomas between Japanese and Western pathologists. J. Gastroenterol. 2001 36 445 456. (Pubitemid 32747204)
6. Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum. Pathol. 1983 14 931 968. (Pubitemid 14209714)
7. Reid BJ, Haggitt RC, Rubin CE et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum. Pathol. 1988 19 166 178. (Pubitemid 18091022)
8. Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum. Pathol. 2001 32 368 378. (Pubitemid 32378298)
9. Kerkhof M, van Dekken H, Steyerberg EW et al. CYBAR study group. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007 50 920 927. (Pubitemid 46850080)
10. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am. J. Gastroenterol. 2001 96 3071 3083. (Pubitemid 33095344)
11. Fahmy M, Skacel M, Gramlich TL et al. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod. Pathol. 2004 17 588 596. (Pubitemid 38868427)
12. Polkowski W, van Lanschot JJ, Ten Kate FJ et al. Value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surg. Oncol. 1995 4 163 171.
13. Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am. J. Surg. Pathol. 2006 30 871 877. (Pubitemid 44264978)
14. Montgomery E, Goldblum JR, Greenson JK et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum. Pathol. 2001 32 379 388. (Pubitemid 32378299)
15. Skacel M, Petras RE, Rybicki LA et al. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am. J. Gastroenterol. 2002 97 2508 2513.
16. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am. J. Gastroenterol. 2001 96 1355 1362. (Pubitemid 32455059)
17. Murray L, Sedo A, Scott M et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 2006 55 1390 1397. (Pubitemid 44476779)
18. Lörinc E, Jakobsson B, Landberg G, Veress B. Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus. Histopathology 2005 46 642 648. (Pubitemid 40834823)
19. Lomo LC, Blount PL, Sanchez CA et al. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort. Am. J. Surg. Pathol. 2006 30 423 435. (Pubitemid 43740142)
20. Odze RD. Diagnosis and grading of dysplasia in Barrett's oesophagus. J. Clin. Pathol. 2006 59 1029 1038. (Pubitemid 44570324)